Anónimo. FDA approves HCV drug for patients who fail to respond to prior treatments that inhibit NS5A. DIA Daily 2017:1. [Ref.ID 101910]

Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, Poropat G, Djurisic S, Weiss KH, Bjelakovic M, Bjelakovic G, Klingenberg SL, Liu JP, Nikolova D, Koretz RL, Gluud C. Direct-acting antivirals for chronic hepatitis C. Cochrane Database of Systematic Reviews 2017;6:6 de junio. [Ref.ID 101674]

Wiktor SZ, Scott JD. What is the impact of treatment for hepatitis C virus infection?. Lancet 2017;390:107-9. [Ref.ID 101668]

Hawkes N. Are new hepatitis C drugs all they’re cracked up to be?. BMJ 2017;357:j2961. [Ref.ID 101659]

Tanimoto T, Tsuda K, Kurokawa T, Mori J, Shimmura H. Essential medicines for universal health coverage. Lancet 2017;389:1880-1. [Ref.ID 101601]

Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]

Anónimo. Antiviraux à action directe: interaction avec les antivitamine K. Prescrire 2017;37:262. [Ref.ID 101533]

Anónimo. MSF, Medecins du Monde challenge Gilead’s sofosbuvir patent. DIA Daily 2017:1. [Ref.ID 101490]

Anónimo. Rifaximine et encéphalopatie hépatique. Prescrire 2017;37:175-6. [Ref.ID 101454]

Bruix J, Qin S, Merle P, Granito A, Huang Y-H, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki J-P, Ollilvier-Hourmand I, Kudo M, Cheng A-L, Llovet JM, Finn RS, LeBerre M-A, Baumhauer A, Meinhardt G, Han G, RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66. [Ref.ID 101370]

Anónimo. Combination HCV therapy achieves high sustained viral response. DIA Daily 2016:5. [Ref.ID 100926]

Anónimo. Sofosuvir: hypertensions artérielles pulmonaires?. Prescrire 2016;36:746. [Ref.ID 100893]

Anónimo. Patients worldwide turning to “buyers clubs” for access to hepatitis C, HIV medications. DIA Daily 2016:7. [Ref.ID 100881]

Anónimo. FDA advisory panel votes to recommend approval of experimental antibiotic. CIDRAP. Center for Infectious Disease Research and Policy 2016:2. [Ref.ID 100879]

Anónimo. Gilead’s hepatitis C drug sales decline. DIA Daily 2016:11. [Ref.ID 100874]

Dam G, Vilstrup H, Watson H, Jepsen P. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites. Hepatology 2016;64:1265-72. [Ref.ID 100853]

Anónimo. Gilead announces promising trial data for hepatitis C combination drug, setbacks for pulmonary artery hypertension and diabetic kidney disease treatment. DIA Daily 2016:4. [Ref.ID 100839]

Anónimo. Clinical trial for rare cancer candidate suspended due to serious liver toxicity. DIA Daily 2016:5. [Ref.ID 100837]

Anónimo. UNICEF reaches deal for vaccines against five childhood diseases for less than $1 per dose. DIA Daily 2016:1. [Ref.ID 100833]

Anónimo. EMA advisory committee conditionally approves obeticholic acid. DIA Daily 2016:4. [Ref.ID 100812]